Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

捷恪卫 - NMPA Drug Approval Details

Approvals/NMPA/Ruxolitinib Phosphate Tablets

Approved

化学药品

Ruxolitinib Phosphate Tablets

Novartis Pharma Schweiz AG🇨🇳 National Medical Products Administration

Approval Date: Dec 7, 2021
Approval ID: 8CYo8neLFVy
Company: Novartis Pharma Schweiz AG
Type: 化学药品

Approval Details

Approval Id: 8CYo8neLFVy
Approval Number: 国药准字HJ20170130
Generic Name: 磷酸芦可替尼片
Generic Name En: Ruxolitinib Phosphate Tablets
Trade Name: 捷恪卫
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 15mg（以芦可替尼计）
Reg Date: 2021-12-07
Expired Date: 2026-12-06
Company Name: Novartis Pharma Schweiz AG
Production Company Name: Novartis Pharma Stein AG
Company Detail Path: /organization/novartis-pharma-schweiz-ag
Production Company Detail Path: /organization/novartis-pharma-stein-ag

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 7, 2021

Approval ID

8CYo8neLFVy

Type

化学药品

Back to NMPA Approvals